Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

A nanocarrier system of d‐a‐tocopheryl polyethylene glycol 1000 succinate (TPGS)‐
functionalized polydopamine‐coated mesoporous silica nanoparticles (NPs) is developed …

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

Abstract Apurinic/apyrimidinic endonuclease 1 (APE1) plays a critical role in the base
excision repair (BER) pathway, which is responsible for the excision of apurinic sites (AP …

Background Investigations of disease incidence, mortality, and disability-adjusted life years
(DALYs) are valuable for facilitating preventive measures and health resource planning. We …

Purpose Recent years have seen a change in the way that clinical trials are being
conducted. There has been a rise of designs more flexible than traditional adaptive and …

Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …